Working… Menu
Trial record 2 of 12 for:    hydrus

Hydrus(R) Microstent New Enrollment Post-Approval Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04553523
Recruitment Status : Recruiting
First Posted : September 17, 2020
Last Update Posted : September 17, 2020
Information provided by (Responsible Party):
Ivantis, Inc.

Brief Summary:
To evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. This trial is a prospective, non-randomized, multicenter, single arm, post approval study. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.

Condition or disease Intervention/treatment Phase
Primary Open Angle Glaucoma Device: Hydrus Microstent Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 330 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Hydrus(R) Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm, Clinical Trial
Actual Study Start Date : August 25, 2020
Estimated Primary Completion Date : May 2024
Estimated Study Completion Date : September 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Single Arm
Subjects with mild to moderate POAG undergoing cataract surgery & implantation of the Hydrus Microstent
Device: Hydrus Microstent
The Hydrus Microstent is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's canal, immediately following placement of a monofocal IOL

Primary Outcome Measures :
  1. Occurrence of clinically significant device malposition [ Time Frame: 24 Months ]
    Rate of occurrence of clinically significant device malposition associated with clinical sequelae

Secondary Outcome Measures :
  1. Occurrence of intraoperative ocular adverse events [ Time Frame: 24 Months ]
    Rate of occurrence of intraoperative ocular adverse events including: hyphema obscuring the surgeon's view, choroidal hemorrhage or effusion, choroidal detachment, significant iris injury or trauma, corneal abrasion, corneal edema, zonular dialysis, cyclodialysis, cyclodialysis cleft, iridodialysis, vitreous loss not associated with the cataract procedure, inadvertent perforation of the sclera, Descemet's membrane detachment

  2. Occurrence of sight threatening post-operative adverse events [ Time Frame: 24 Months ]
    Rate of occurrence of sight threatening, post-operative adverse events including: endophthalmitis, corneal decompensation, severe retinal detachment, severe choroidal hemorrhage, severe choroidal detachment, aqueous misdirection

  3. Occurrence of other postoperative ocular adverse events [ Time Frame: 24 Months ]
    Rate of occurrence of other postop ocular adverse events including: anterior uveitis/iritis, non-persistent & persistent, BCVA loss of 2 lines or more, chronic pain, device migration, device obstruction, PAS, ocular secondary surgical interventions for IOP or glaucoma management, hypotony at or after 1 month postop, hyphema, corneal opacification, corneal edema persisting or severe corneal edema, other retinal complications, elevated mean IOP >/=10mmHg vs screening, iris prolapse/wound incarceration, significant foreign body sensation at or after 3 months postop, surgical re-intervention, worsening of visual field.

Other Outcome Measures:
  1. Occurrence of non-clinically significant device malposition [ Time Frame: 24 Months ]
    Rate of occurrence of device malposition that is not clinically significant (ie, does not result in clinical sequelae)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • An operable age-related cataract with BCVA of 20/40 or worse
  • Diagnosis of POAG treated with no more than 4 topical hypotensive medications
  • Optic nerve appearance characteristic of glaucoma
  • Medicated IOP </= 31mmHg

Exclusion Criteria:

  • Closed angle forms of glaucoma
  • Congenital or developmental glaucoma
  • Secondary glaucoma
  • Use of more than 4 ocular hypotensive medications
  • Previous argon laser trabeculoplasty, trabeculectomy, tube shunts, or any other prior filtration or cilioablative surgery
  • Prior surgery with implanted device or other surgery involving the trabecular meshwork or Schlemm's canal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04553523

Layout table for location contacts
Contact: Richard Hope, MD 949-333-1310

Layout table for location information
United States, California
Sacramento Eye Consultants, A Medical Corporation Recruiting
Sacramento, California, United States, 95815
Contact: Jacob Brubaker, MD   
United States, Colorado
Eye Center of Northern Colorado Recruiting
Fort Collins, Colorado, United States, 80528
Contact: Kent Bashford, MD   
United States, Michigan
Fraser Eye Care Center Recruiting
Fraser, Michigan, United States, 48026
Contact: Mahdi Basha, MD   
United States, Minnesota
North Suburban Eye Specialists Recruiting
Coon Rapids, Minnesota, United States, 55433
Contact: George Wandling, MD   
United States, Nevada
Center for Sight Recruiting
Las Vegas, Nevada, United States, 89145
Contact: Eva Liang, MD   
United States, North Carolina
Carolina Eye Associates Recruiting
Southern Pines, North Carolina, United States, 28387
Contact: Winston Garris, MD   
United States, Ohio
Cincinnati Eye Institute Recruiting
Cincinnati, Ohio, United States, 45242
Contact: Anup Khatana, MD   
United States, Texas
El Paso Eye Surgeons, PA Not yet recruiting
El Paso, Texas, United States, 79902
Contact: Mark Gallardo, MD   
Texas Eye & Laser Center Recruiting
Hurst, Texas, United States, 76054
Contact: Jerry Hu, MD   
United States, Wisconsin
The Eye Centers of Racine and Kenosha LTD Not yet recruiting
Kenosha, Wisconsin, United States, 53142
Contact: Inder Paul Singh, MD   
Sponsors and Collaborators
Ivantis, Inc.
Layout table for additonal information
Responsible Party: Ivantis, Inc. Identifier: NCT04553523    
Other Study ID Numbers: CP 18-001
First Posted: September 17, 2020    Key Record Dates
Last Update Posted: September 17, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases